SEC Form 4 · accession 0001209191-15-056900
Regulus Therapeutics Inc. · RGLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul C Grint
Officer — President & CEO · Director
Period of report
Jun 25, 2015
Accepted (ET)
Jun 26, 2015 · 5:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001505512
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $10.22 | Jun 25, 2015 | A | 500,000 | A | — | Jun 24, 2025 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F1Twenty-Five percent of the options will vest on the one year anniversary date of the grant and the balance of the shares will vest in a series of thirty-six equal monthly installments thereafter, such that the option is fully vested on the fourth anniversary of the date of grant.